Press Releases
Jul 20, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application...

Jul 9, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted PADCEV®...

Jun 25, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for...

EXPLORE ALL US PRESS RELEASES

Articles
May 27, 2021

Astellas is at an inflection point in our evolution, facing opportunities presented by our growing pipeline, but amidst a rapidly changing environment that is transforming the ways every segment...

Jul 14, 2021

Improved score marks continuing effort in growing inclusive culture to support people with disabilities For the second year in a row, Astellas has been included in the Disability Equality Index as...

Jun 15, 2021

Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products